Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 1, 1997, Pages 18-22

  Caron, Philippe ^a   Morange Ramos, Isabelle ^b   Cogne, Muriel ^a   Jaquet, Philippe ^b  

^a CHU RANGUEIL   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; EMPTY SELLA SYNDROME; FEMALE; FOLLOW UP; GALLSTONE; GASTROINTESTINAL TOXICITY; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONE INHIBITION; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICROADENOMA; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME;

ACROMEGALY; ADENOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PITUITARY NEOPLASMS; SOMATOSTATIN; THYROID GLAND;

EID: 0031022831     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.82.1.18     Document Type: Article

References (28)

1. Harris AG, Prestele H, Herold K, Boerlin V. 1987 Long-term efficacy of Sandostatin (SMS 201-995, octreotide) in 178 acromegalic patients. Results from the International Multicentre Acromegaly Study Group. In: Lamberts SWJ, ed. Sandostatin in the treatment of acromegaly. Concensus round table. Amsterdam: Springer; Berlin; 117-125.
2. Lamberts SWJ, Uitterlinden P, Del Pozo E. 1987 SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 65:703-710.
3. Sassolas G, Harris AG, James-Deidier A., and the French SMS. 201-995 acromegaly study group. 1990 Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 71:391-397.
4. Heron I, Thomas F, Dero M, et al. 1993 Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab. 76:721-727.
5. Johnson MR, Chowdrey HS, Thomas F, Grint C, Lightman SL. 1994 Pharmacokinetics and efficacy of the long-acting somatostatin analogue somatuline in acromegaly. Eur J Endocrinol. 130:229-234.
6. Morange I, de Boisvilliers F, Chanson P, et al. 1994 Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab. 79:145-151.
7. Giusti M, Gussoni G, Cuttica CM, Giordano G, and the Italian Multicenter Slow Release Lanreotide Study Group. 1996 Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly; six-month report on an Italian multicenter study. J Clin Endocrinol Metab. 81:2089-2097.
8. Caron Ph, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. 1995 Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol. 132:320-325.
9. Sassolas G, Khalfallah Y, Chayvialle JA, et al. 1989 Effects of the somatostatin analog BIM 23014 on the secretion of growth hormone, thyrotropin, and digestive peptides in normal men. J Clin Endocrinol Metab. 68:239-246.
10. Heron I, Thomas F, Dero M, et al. 1993 Traitement de l'acromégalie par une forme à libération prolongée du lanréotide. Presse Med. 22:526-531.
11. Ikuyama S, Nawata H, Kato KI, Ibayashi H, Nakagaki H. 1986 Plasma growth hormone responses to somatostatin (SRIH) and SRIH receptors in pituitary adenomas in acromegalic patients. J Clin Endocrinol Metab. 62:729-733.
12. Reubi JC, Landolt AM. 1989 The growth hormone response to octreotide in acromegaly correlates with adenoma sandostatin receptors. J Clin Endocrinol Metab. 68:844-850.
13. Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. 1996 Octreotide. N Engl J Med. 334: 246-254.
14. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. 1994 Effects of a slow-release formulation of the new somatostatin analogue in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 40:421-428.
15. Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC. 1995 Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab. 80:3267-3272.
16. Vance ML, Harris AG. 1991 Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch Internal Med. 151:1573-1578.
17. Newman CB, Melmed S, Snyder PJ, et al. 1995 Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients a clinical research center study. J Clin Endocrinol Metab. 80:2768-2775.
18. Bates AS, Van't Hoff W, Jones JM, Clayton RN. 1993 An audit of outcome of treatment in acromegalv. Q J Med. 86:293-299.
19. Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertso HK. 1994 Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf). 41:95-102.
20. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. 1995 Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 80:3395-3402.
21. Quabbe HJ, Plockinger U. 1989 Dose-response study and long-term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 68:873-881.
22. Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. 1985 Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med. 313:1576-1580.
23. Lamberts SWJ, Uitterlinden P, Schuijff PC, Klijn JG. 1988 Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatostatin-C measurements in dose adjustement, and the definition of a biochemical 'cure'. Clin Endocrinol (Oxf). 29:411-420.
24. Ezzat S, Snyder Pj, Young WF, et al. 1992 Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 117:711-718.
25. Christensen SE, Weeke J, Kaal A, Harris AG, Orskov H. 1992 SMS 201-995 and thyroid function in aacromegaly: acute, intermediate, and long-term effects. Horm Metab Res. 24:237-239.
26. Dowling RH, Hussaini GM, Besser GM, Wass JAH. 1992 Gallstones during octreotide therapy. Metabolism. 141:22-33.
27. Eastman RC, Arakaki RF, Shawker T, et al. 1992 A prospective examination of octreotide-induced gallbladder changes in acromegaly. Clin Endocrinol (Oxf). 36:265-269.
28. Tauber JP, Poncet MF, Harris AG, et al. 1995 The impact of continuous subcutaneous infusion of octreotide on gallstone formation in acromegalic patients. J Clin Endocrinol Metab. 80:3262-3266.